Biotechnology
Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe
2025, one of the industry's premier gatherings for innovation in protein and
antibody engineering, Tsingke Biotech highlighted its latest acceleratedprotein
2025-11-19 22:17
855
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IN...
2025-11-19 20:08
599
BIOVOZ and the University of Auckland Join Forces to Lead the Next Frontier in Anti-Aging Research
From Ingredient Supplementation to Gene Regulation: BIOVOZ and the University of Auckland Pioneer a New Era in Beauty Science AUCKLAND, New Zealand, Nov. 19, 2025 /PRNewswire/ -- Leading beauty brand BIOVOZ has announced a strategic research partnership with the University ofAuckland, marking a ...
2025-11-19 15:02
585
Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care
JERUSALEM, Nov. 19, 2025 /PRNewswire/ -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by theBiomedical Advanced Research and Developmen...
2025-11-19 13:01
414
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restric...
2025-11-19 08:00
907
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxali...
2025-11-19 05:15
1939
CRScube acquires Mednet to expand global eClinical capabilities
SEOUL, South Korea and MINNEAPOLIS, Nov. 18, 2025 /PRNewswire/ -- CRScube has announced the successful acquisition of Mednet, marking a key milestone in its global strategic growth and expansion into the North American market. The transaction unites two respected eClinical technology vendors with...
2025-11-18 17:00
871
INSTITUTE OF NEURODIVERSITY, NEUROPOWER WORLD, AND SINGAPORE BRINGS NEURODESIGN TO THE FOREFRONT OF SINGAPORE'S URBAN PLANNING
Hazleen Ahmad, Founder of Neuropower World and Chair & Founder of ION Singapore, to launch pilot projects and training programmes embedding neurodesign into workplaces, housing, parks, and transport hubs SINGAPORE, Nov. 18, 2025 /PRNewswire/ -- The Institute of Neurodiversity (ION) Singapore and ...
2025-11-18 09:00
741
Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract de...
2025-11-17 22:26
898
Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs
BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a subst...
2025-11-17 22:15
856
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection...
2025-11-17 22:06
1124
AKA Foods Secures 17.2 Million Dollars in Seed Funding to launch the world's first secure AI system for food innovation
New AKA Studio consolidates organisational knowledge, incorporates sensory
evaluation, and applies AI assistants to guide formulation and optimisation
AMSTELVEEN, Netherlands, Nov. 17, 2025 /PRNewswire/ -- AKA Foods Ltd
2025-11-17 17:00
705
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
HONG KONG, Nov. 17, 2025 /PRNewswire/ -- The APAC Precision Oncology Conference
2025
2025-11-17 13:45
796
Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
* Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for patients acrossJapan * Similar marketing authorization...
2025-11-14 17:43
775
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka; President and COO:Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirm...
2025-11-14 16:00
818
Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal
HONG KONG, Nov. 14, 2025 /PRNewswire/ -- On 13 November 2025, Hong Kong Economic Journal (HKEJ), Hong Kong's first Chinese-language financial newspaper, hosted the "ESG & Sustainability Awards of Excellence 2025" ceremony. At the event, Fosun International received the "ESG & Corporate Sustainab...
2025-11-14 09:00
2375
Amorepacific Named CES Innovation Award Honoree for Advanced Electronic Skin Platform
- Co-developed by Amorepacific and MIT, Skinsight™ receives recognition as the company's seventh consecutive win at CES - Applied in substantiating the efficacy of a Sulwhasoo product, with functionality in skin-aging analytics backed by published research SEOUL, South Korea, Nov. 14, 2025 /PR...
2025-11-14 09:00
827
LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) with a leading global pharmaceutical company for its proprietary blo...
2025-11-13 21:00
831
KHB Showcases the Enhanced FOCUS PEGASUS MF200 -- Redefining Efficiency in Veterinary Diagnostics
XI'AN, China, Nov. 13, 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., a subsidiary of KHB Group and an innovator in veterinary point-of-care testing (POCT) solutions, presents the enhanced FOCUS PEGASUS MF200 Automatic Multifunctional Veterinary Analyzer — a next-generation system ...
2025-11-13 15:18
780
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 16:12
836
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 309 media titles]
2025-12-04 16:00
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Hyundai Motor Group Fosters Collaboration with Hydrogen Industry Leaders at Hydrogen Council Global CEO Summit
[Picked up by 295 media titles]
2025-12-04 15:00
Most Read
Empowering AI Acceleration: openEuler Unveils First SuperPoD-Ready OS and Welcomes AMD, Inspur Cloud, and Digital China
2025-11-29 15:37
2564
Manulife Donates HK$20 Million to Support Communities Affected by Tai Po Fire
2025-11-28 17:58
2499
